Bioasis to Present at Investor & Industry Conferences in January 2019

GUILFORD, Conn.--(BUSINESS WIRE)-- Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB³™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that members of management will present at the following investor and industry conferences in January 2019:

2nd Annual Neuroscience Innovation Forum

• Mark Day, Ph.D., director, president and chief executive officer will deliver the Bioasis company presentation at the 2^nd Annual Neuroscience Innovation Forum on Mon., Jan. 6, 2019 at 12:05 p.m. PT in the Heritage Room at the Marines' Memorial Club & Hotel, San Francisco.
• Dr. Mark Day will also co-chair the Advances in Rare & Orphan Diseases panel on Mon., Jan. 6 at 2:10 p.m. PT.

Biotech Showcase™

• Dr. Mark Day will deliver the Bioasis company presentation at Biotech Showcase on Tues., Jan 7, 2019 at 10 a.m. PT in the Yosemite C Ballroom at the Hilton San Francisco Union Square, San Francisco.

PepTalk - The Protein Science Week

• Mei Mei Tian, Ph.D., vice president, head of external research will present, "The xB³ Platform Delivers a Protein-Based Interleukin 1 Receptor Antagonist across the BBB and Ameliorates Neuropathic Pain in a Preclinical Model" at PepTalk – The Protein Science Week on Mon., Jan. 14, 2019 at 11:45 a.m. PT at the Hilton San Diego Bayfront, San Diego.

On behalf of the Board of Directors of Bioasis Technologies Inc.

Mark Day, Ph.D., Director, President & Chief Executive Officer

ABOUT BIOASIS

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB³™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005774/en/